215 related articles for article (PubMed ID: 1092759)
1. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
Likhite VV
J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
[TBL] [Abstract][Full Text] [Related]
2. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
Purnell DM; Bartlett GL; Kreider JW; Biro TG
Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
[TBL] [Abstract][Full Text] [Related]
3. Role of T-cell subsets in the destruction of established metastases of 13762A rat mammary adenocarcinoma.
Howell LE; Kreider JW; Bartlett GL
J Natl Cancer Inst; 1986 Jul; 77(1):187-93. PubMed ID: 3487670
[TBL] [Abstract][Full Text] [Related]
4. The delayed and lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with use of killed Bordetella pertussis.
Likhite VV
Cancer Res; 1974 May; 34(5):1027-30. PubMed ID: 4363061
[No Abstract] [Full Text] [Related]
5. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice.
Wolmark N; Fisher B
Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513
[No Abstract] [Full Text] [Related]
6. Lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with intratumor injection of killed Corynebacterium parvum.
Likhite VV; Halpern BN
Cancer Res; 1974 Feb; 34(2):341-4. PubMed ID: 4810906
[No Abstract] [Full Text] [Related]
7. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
Likhite VV
J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
[TBL] [Abstract][Full Text] [Related]
8. Rejection of mammary adenocarcinoma cell tumors and the prevention of progressive growth of incipient metastases following intratumor permeation with killed Bordetella pertussis.
Likhite VV
Cancer Res; 1974 Oct; 34(10):2790-4. PubMed ID: 4370327
[No Abstract] [Full Text] [Related]
9. Spontaneous immune rejection of intraocular tumors in mice.
Niederkorn JY; Meunier PC
Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
Kreider JW; Bartlett GL; Purnell DM; Webb S
Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
[TBL] [Abstract][Full Text] [Related]
11. Splenic alterations during mammary tumorigenesis: diverse effects on different immune parameters.
Paul RD; Ghaffar A; Sigel MM; Charyulu V; Lopez DM
Anticancer Res; 1981; 1(2):63-9. PubMed ID: 6214206
[TBL] [Abstract][Full Text] [Related]
12. Immune response to inactivated syngeneic mammary adenocarcinoma cells. I. Role and regulation of antibody synthesis in DBA/2 mice.
DeLustro F; Haskill JS
J Natl Cancer Inst; 1980 Jan; 64(1):125-30. PubMed ID: 6928037
[TBL] [Abstract][Full Text] [Related]
13. Immunologic factors influencing the intra-tumor localization of ADCC effector cells.
Haskill S; Parthenais E
J Immunol; 1978 Jun; 120(6):1813-7. PubMed ID: 659877
[TBL] [Abstract][Full Text] [Related]
14. Effect of C. parvum on intratumor immunity to the T1699 mammary adenocarcinoma.
Haskill S; Ritter F; Becker S
J Immunol; 1980 Jul; 125(1):454-8. PubMed ID: 6247400
[No Abstract] [Full Text] [Related]
15. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
[TBL] [Abstract][Full Text] [Related]
16. Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity.
Giovarelli M; Santoni A; Forni G
J Immunol; 1985 Nov; 135(5):3596-603. PubMed ID: 3930610
[TBL] [Abstract][Full Text] [Related]
17. Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts.
Fujimoto S; Greene MI; Sehon AH
J Immunol; 1976 Mar; 116(3):791-9. PubMed ID: 1082894
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-mediated, antibody-dependent destruction of tumor cells in DBA/2 mice: in vitro identification of an in situ mechanism.
Key M; Haskill S
J Natl Cancer Inst; 1981 Jan; 66(1):103-10. PubMed ID: 7005500
[TBL] [Abstract][Full Text] [Related]
19. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
